Intelligent Telehealth in Pharmacovigilance: A Future Perspective

被引:17
|
作者
Edrees, Heba [1 ,2 ,3 ]
Song, Wenyu [1 ,3 ]
Syrowatka, Ania [1 ,3 ]
Simona, Aurelien [1 ,3 ]
Amato, Mary G. [1 ]
Bates, David W. [1 ,3 ,4 ]
机构
[1] Brigham & Womens Hosp, Div Gen Internal Med, 75 Francis St, Boston, MA 02115 USA
[2] MCPHS Univ, Dept Pharm Practice, Boston, MA USA
[3] Harvard Med Sch, 1620 Tremont St,3rd Floor, Boston, MA 02120 USA
[4] Harvard Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA
关键词
ELECTRONIC HEALTH RECORDS; ADVERSE DRUG-REACTIONS; ARTIFICIAL-INTELLIGENCE; CHRONIC DISEASES; TELEMEDICINE; METAANALYSIS; VALIDATION; MANAGEMENT; SIGNALS; EVENTS;
D O I
10.1007/s40264-022-01172-5
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Pharmacovigilance improves patient safety by detecting and preventing adverse drug events. However, challenges exist that limit adverse drug event detection, resulting in many adverse drug events being underreported or inaccurately reported. One challenge includes having access to large data sets from various sources including electronic health records and wearable medical devices. Artificial intelligence, including machine learning methods, such as natural language processing and deep learning, can detect and extract information about adverse drug events, thus automating the pharmacovigilance process and improving the surveillance of known and documented adverse drug events. In addition, with the increased demand for telehealth services, for managing both acute and chronic diseases, artificial intelligence methods can play a role in detecting and preventing adverse drug events. In this review, we discuss two use cases of how artificial intelligence methods may be useful to improve the quality of pharmacovigilance and the role of artificial intelligence in telehealth practices.
引用
收藏
页码:449 / 458
页数:10
相关论文
共 50 条
  • [1] Intelligent Telehealth in Pharmacovigilance: A Future Perspective
    Heba Edrees
    Wenyu Song
    Ania Syrowatka
    Aurélien Simona
    Mary G. Amato
    David W. Bates
    Drug Safety, 2022, 45 : 449 - 458
  • [2] HISTORICAL PERSPECTIVE AND FUTURE OF PHARMACOVIGILANCE
    Laporte, J. R.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 119 : 6 - 6
  • [3] Vaccine pharmacovigilance in India: Current context and future perspective
    Meher, Bikash Ranjan
    INDIAN JOURNAL OF PHARMACOLOGY, 2019, 51 (04) : 243 - 247
  • [4] Pharmacovigilance in perspective
    Meyboom, RHB
    Egberts, ACG
    Gribnau, FWJ
    Hekster, YA
    DRUG SAFETY, 1999, 21 (06) : 429 - 447
  • [5] Pharmacovigilance in Perspective
    Ronald H. B. Meyboom
    Antoine C. G. Egberts
    Frank W. J. Gribnau
    Yechiel A. Hekster
    Drug Safety, 1999, 21 : 429 - 447
  • [6] The Future of Pharmacovigilance
    Arlett, P.
    DRUG SAFETY, 2015, 38 (10) : 938 - 938
  • [7] A perspective on magnetic microfluidics: Towards an intelligent future
    Zhang, Yi
    Zhou, Aiwu
    Chen, Songlin
    Lum, Guo Zhan
    Zhang, Xiaosheng
    BIOMICROFLUIDICS, 2022, 16 (01)
  • [8] Another Perspective in Pharmacovigilance
    van Puijenbroek, E.
    DRUG SAFETY, 2015, 38 (10) : 944 - 944
  • [9] Innovations for the Future of Pharmacovigilance
    June S. Almenoff
    Drug Safety, 2007, 30 : 631 - 633
  • [10] Innovations for the future of pharmacovigilance
    Almenoff, June S.
    DRUG SAFETY, 2007, 30 (07) : 631 - 633